Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Accelerated Infliximab Infusions (FAST)
2008-007519-34Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of infliximab in inflammatory bowel disease (IBD), sponsored by UZ Leuven. Primary endpoint: Tolerance of 30-minute infliximab infusions. Started Mar 2009; status: completed.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on 2008-007519-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007519-34.